Annals of Clinical and Translational Neurology · 2023 · 28 citations · 29 references
MedicineNeurologyNeuroscienceImmunopathologyNeuroimmunologyNeuropathologyAutoimmune Neurological DisordersDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisOptic NeuritisOptic NeuropathiesApparent Diffusion Coefficient AnalysisAutoimmune DemyelinationCerebrospinal Fluid Oligoclonal BandsFollow-up DurationImmune-mediated DemyelinationInflammatory DemyelinationMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseMyelin-associated Glycoprotein
OBJECTIVE: To describe demographic, clinical, and radiographic features of tumefactive demyelination (TD) and identify factors associated with severe attacks and poor outcomes. METHODS: Retrospective review of TD cases seen at Mayo Clinic, 1990-2021. RESULTS: Of 257 patients with TD, 183/257 (71%) fulfilled the 2017 multiple sclerosis (MS) McDonald criteria at the last follow-up, 12/257 (5%) had myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), 0 had aquaporin-4-IgG seropositive neuromyelitis optic spectrum disorders (AQP4+ NMOSD), and 62/257 (24%) were cryptogenic. Onset before age 18 was present in 18/257 (7%). Female to male ratio was 1.3:1. Cerebrospinal fluid oligoclonal (CSF) bands were present in 95/153 (62%). TD was the first demyelinating attack in 176/257 (69%). At presentation, 59/126 (47%) fulfilled Barkhof criteria for dissemination in space, 59/100 (59%) had apparent diffusion coefficient (ADC) restriction, and 57/126 (45%) had mass effect. Despite aggressive clinical presentation at onset, 181/257 (70%) of patients remained fully ambulatory (Expanded Disability Status Scale [EDSS] ≤4) after a 3.0-year median follow-up duration. Severe initial attack-related disability (EDSS ≥4) was more common in patients with motor symptoms (81/143 vs. 35/106, p < 0.0001), encephalopathy (20/143 vs. 2/106, p < 0.0001) and ADC restriction on initial MRI (42/63 vs. 15/33, p = 0.04). Poor long-term outcome (EDSS ≥4) was more common in patients with older onset age (41.9 ± 15 vs. 36.8 ± 15.6, p = 0.02) and motor symptoms at onset (49/76 vs. 66/171, p < 0.0001). INTERPRETATION: Most TD patients should be considered part of the MS spectrum after excluding MOGAD and NMOSD. Motor symptoms and older age at presentation portend a poor outcome.
29
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al. · Neurology · 2015 · 4.5K citations · Full text
Medicine, Neurology, Neuroscience +15
Annabel M. Ruiter, Rosemarijn R. J. Somanje-Bolweg, Erik van Gorsel et al. · PubMed · 2017 · 1.8K citations · Full text
Patrick Waters, Andrew McKeon, Maria Isabel Leite et al. · Neurology · 2012 · 526 citations · Full text
Life Sciences, Immunology, Neurology +14